Arvee Laborat.

Who are the top shareholders of the Arvee Laborat.?

The top shareholders of Arvee Laborat are Shalin Sudhakarbhai Patel, holding 36.68%, and Gitaben Dinehsbhai Patel, with 9.98%. Individual investors collectively own 26.33%, with no mutual funds or foreign institutional investors involved.

The top shareholders of Arvee Laborat include Shalin Sudhakarbhai Patel, who is the promoter with the highest holding at 36.68%. The highest public shareholder is Gitaben Dinehsbhai Patel, holding 9.98%. Additionally, individual investors collectively hold 26.33% of the company's shares. There are no mutual funds or foreign institutional investors currently holding shares in the company.

how big is Arvee Laborat.?

As of Jun 06, Arvee Laboratories (India) Ltd has a market capitalization of 196.00 Cr and reported net sales of 38.49 Cr and net profit of 2.14 Cr over the latest four quarters. Shareholder's funds are 29.11 Cr, with total assets of 38.20 Cr as of Mar'24.

Market Cap: As of Jun 06, Arvee Laboratories (India) Ltd has a market capitalization of 196.00 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes the periods of Mar'25, Dec'24, Sep'24, and Jun'24, is 38.49 Cr. The sum of Net Profit for the same quarters is 2.14 Cr. This data is presented on a Standalone basis.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the latest annual period ending in Mar'24. Shareholder's Funds are reported at 29.11 Cr, while Total Assets amount to 38.20 Cr.

What does Arvee Laborat. do?

Arvee Laboratories (India) Ltd manufactures specialized chemicals and is classified as a Micro Cap company. As of March 2025, it reported net sales of 6 Cr and a net profit of 0 Cr, with a market cap of Rs 196 Cr.

Overview: <BR>Arvee Laboratories (India) Ltd is engaged in the manufacturing of specialized chemicals and operates within the Chemicals & Petrochemicals industry, classified as a Micro Cap company.<BR><BR>History: <BR>The company was incorporated in 2012 as a Private Limited Company and later converted to a Public Limited Company in 2017. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>- Net Sales: 6 Cr (Quarterly Results - Mar 2025) <BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>- Market Cap: Rs 196 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>- P/E: 92.00 <BR>- Industry P/E: 47 <BR>- Dividend Yield: 0.00% <BR>- Debt Equity: -0.16 <BR>- Return on Equity: 6.85% <BR>- Price to Book: 6.27 <BR><BR>Contact Details: <BR>Address: 49/3 B Shyamal Row House, 100 Feet Road Satelitte Ahmedabad Gujarat : 380015 <BR>Tel: 91-79-26749036/37/38 <BR>Email: shalin.patel@arveelabs.com <BR>Website: http://www.arveelabs.com

When is the next results date for Arvee Laborat.?

No Upcoming Board Meetings

What is the bonus history of the Arvee Laborat.?

Arvee Laboratories (India) Ltd issued a 1:1 bonus on October 13, 2020, with a record date of October 14, 2020, allowing shareholders to receive one additional share for each share held.

Arvee Laboratories (India) Ltd has a bonus history that includes a 1:1 bonus issue announced with an ex-date of October 13, 2020. The record date for this bonus was October 14, 2020. This means that shareholders on record as of that date received an additional share for each share they held.

Has Arvee Laborat. declared dividend?

No Dividend History Available

Who are the peers of the Arvee Laborat.?

Peers of Arvee Laborat. include Indian Emuls, Hindcon Chemical, Shri Ahimsa, and others, with similar management risks and growth ratings. All peers, including Arvee Laborat., have a 1-year and six-month return of 0.00%.

Peers: The peers of Arvee Laborat. are Indian Emuls, Hindcon Chemical, Shri Ahimsa, Indian Phosphate, Hi-Green Carbon, Vital Chemtech, Jocil, Paragon Fine, Par Drugs & Che., Mahickra Chem.<BR><BR>Quality Snapshot: Excellent management risk is observed at Indian Emuls, Shri Ahimsa, and Paragon Fine, while Average management risk is found at Hindcon Chemical, Hi-Green Carbon, Vital Chemtech, Jocil, Par Drugs & Che., Mahickra Chem, and Arvee Laborat. Growth is rated as Excellent for Indian Emuls, while Below Average growth is noted for Hindcon Chemical, Shri Ahimsa, Indian Phosphate, Vital Chemtech, Jocil, Paragon Fine, Par Drugs & Che., Mahickra Chem, and Arvee Laborat. Capital Structure is Excellent at Hindcon Chemical, Shri Ahimsa, Jocil, and Par Drugs & Che., while Average is seen at Indian Emuls and Vital Chemtech, and Good at Indian Phosphate, Hi-Green Carbon, Paragon Fine, and Arvee Laborat.<BR><BR>Return Snapshot: All peers, including Arvee Laborat., have a 1-year return of 0.00%, indicating no variation among them. Therefore, there is no peer with a higher or lower return compared to Arvee Laborat. Additionally, all peers have a six-month return of 0.00%, indicating no negative returns.

What is the technical trend for Arvee Laborat.?

As of June 5, 2025, Arvee Laborat's technical trend is neutral with a slight bearish inclination in the short term, driven by mixed MACD signals and mildly bearish daily moving averages.

As of 5 June 2025, the technical trend for Arvee Laborat has changed from mildly bullish to sideways. The weekly MACD remains bullish, while the monthly MACD is mildly bearish, indicating mixed signals. The Bollinger Bands show a mildly bullish stance on the weekly chart but are sideways on the monthly chart. Moving averages on the daily timeframe are mildly bearish, suggesting short-term weakness. The KST and Dow Theory both indicate a mildly bullish outlook on the weekly and monthly charts. Overall, the current technical stance is neutral with a slight bearish inclination in the short term, driven primarily by the daily moving averages and the mixed signals from the MACD.

Who are in the management team of Arvee Laborat.?

As of March 2020, the management team of Arvee Laborat includes Shalin Sudhakarbhai Patel (Chairman & Managing Director), Shalin Bharat Chokshi (Whole-time Director), and seven Independent Directors: Chandrakala Ashok Bhatt, Vishal Nitin Mehta, Amishkumar Maheshkumar Shah, Paragbhai Manubhai Shah, Neetu Jalan, and Sachin Kanwarlal Kansal. Each member contributes to the company's governance and strategic direction.

As of March 2020, the management team of Arvee Laborat consists of the following individuals:<BR><BR>1. Shalin Sudhakarbhai Patel - Chairman & Managing Director<BR>2. Shalin Bharat Chokshi - Whole-time Director<BR>3. Chandrakala Ashok Bhatt - Independent Director<BR>4. Vishal Nitin Mehta - Independent Director<BR>5. Amishkumar Maheshkumar Shah - Independent Director<BR>6. Paragbhai Manubhai Shah - Independent Director<BR>7. Neetu Jalan - Independent Director<BR>8. Sachin Kanwarlal Kansal - Independent Director<BR><BR>Each member plays a significant role in the governance and strategic direction of the company.

How has been the historical performance of Arvee Laborat.?

Arvee Laborat has experienced significant fluctuations in financial performance, with net sales and profits declining from March 2023 to March 2025, despite slight improvements in cash flow. Key metrics such as operating profit and earnings per share also decreased during this period.

Answer:<BR>The historical performance of Arvee Laborat shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Arvee Laborat's net sales have varied considerably, peaking at 62.48 Cr in March 2023 before declining to 38.49 Cr in March 2025. The total operating income followed a similar trend, reaching its highest at 62.48 Cr in March 2023 and dropping to 38.49 Cr in March 2025. The raw material cost has also seen an increase, from 18.87 Cr in March 2025 compared to 16.98 Cr in March 2024, while total expenditure excluding depreciation decreased from 54.07 Cr in March 2023 to 34.87 Cr in March 2025. Operating profit (PBDIT) has fluctuated, with a high of 8.63 Cr in March 2023 and a decrease to 4.28 Cr in March 2025. Profit before tax showed a decline from 6.17 Cr in March 2023 to 2.87 Cr in March 2025, while profit after tax also decreased from 4.12 Cr in March 2023 to 2.15 Cr in March 2025. The earnings per share (EPS) reflected this trend, dropping from 3.74 in March 2023 to 1.95 in March 2025. On the balance sheet, total assets decreased from 38.69 Cr in March 2023 to 38.20 Cr in March 2024, while total liabilities remained relatively stable. Cash flow from operating activities improved slightly from 2.00 Cr in March 2023 to 3.00 Cr in March 2024, with a net cash inflow of 1.00 Cr in March 2024. Overall, the financial performance of Arvee Laborat indicates a challenging period with declining revenues and profits, despite some improvements in cash flow.

Is Arvee Laborat. overvalued or undervalued?

As of November 17, 2025, Arvee Laboratories is considered overvalued and risky, with a PE ratio of 461.66 and an EV to EBITDA of 171.93, significantly higher than its peers, despite a strong historical stock performance.

As of 17 November 2025, the valuation grade for Arvee Laboratories has moved from very expensive to risky, indicating a significant shift in its perceived value. The company is currently considered overvalued. Key ratios highlight this concern, with a PE ratio of 461.66, an EV to EBITDA of 171.93, and a ROE of just 1.27%. <BR><BR>In comparison to its peers, Arvee's valuation metrics are starkly higher; for instance, Solar Industries has a PE of 95.31 and Gujarat Fluoroch at 57.85, both categorized as very expensive. The high PE ratio and negative EV to EBIT of -178.80 further underscore the risk associated with Arvee's current valuation. Despite a strong performance over the last five years, where the stock returned 303.78% compared to the Sensex's 102.06%, the current valuation suggests that investors should approach with caution.

Why is Arvee Laboratories (India) Ltd falling/rising?

As of 19-May, Arvee Laboratories (India) Ltd's stock price is rising to 163.89, driven by strong market interest and increased investor participation. However, despite recent positive financial results, the stock shows weak long-term fundamentals, raising concerns about its future profitability.

As of 19-May, Arvee Laboratories (India) Ltd's stock price is rising, currently at 163.89, reflecting a change of 8.49 (5.46%) upwards. This increase can be attributed to several factors. Firstly, the stock has outperformed its sector by 4.69% today, indicating strong market interest. Additionally, there has been a notable rise in investor participation, with delivery volume on 18 May increasing by 167.73% compared to the 5-day average, suggesting heightened trading activity and confidence among investors.<BR><BR>Furthermore, the company reported positive financial results for the latest six months, with net sales growing by 33.98% to Rs 20.58 crore and a higher profit after tax (PAT) of Rs 2.35 crore. This performance has contributed to the stock's market-beating returns over the past year, where it generated a return of 10.32%, significantly outperforming the broader market index, Sensex, which declined by 5.32% in the same period.<BR><BR>Despite these positive indicators, it is important to note that the stock has a weak long-term fundamental strength, evidenced by a -20.49% compound annual growth rate (CAGR) in operating profits over the last five years and a relatively low return on equity (ROE) of 6.6. This suggests that while the stock is currently rising, there are underlying concerns regarding its long-term profitability and valuation compared to peers.

Which are the latest news on Arvee Laborat.?

Are Arvee Laboratories (India) Ltd latest results good or bad?

Arvee Laboratories (India) Ltd's latest results show strong year-on-year growth with a 642.86% increase in net profit and a 67.44% rise in revenue, but a significant quarterly decline in profitability and margins raises concerns about sustainability. Overall, the results are mixed, reflecting both positive growth and operational challenges.

Arvee Laboratories (India) Ltd's latest results present a mixed picture. In Q4 FY26, the company reported a net profit of ₹0.52 crore, which is a significant year-on-year increase of 642.86% compared to the same quarter last year. However, this figure represents a sharp decline of 71.58% from the previous quarter, indicating considerable volatility in profitability.<BR><BR>On the revenue side, the company achieved ₹10.80 crore, marking a healthy growth of 67.44% year-on-year and a 10.43% increase quarter-on-quarter. This growth in revenue is a positive sign, but it is overshadowed by the substantial drop in net profit and operating margins. The operating margin fell to 10.19%, down from 16.56% in the previous quarter, and the PAT margin decreased dramatically to 4.81% from 18.71%.<BR><BR>Investors reacted positively to the year-on-year profit growth, as evidenced by a 5.46% increase in the stock price following the results announcement. However, the company's high valuation at 84 times trailing earnings and ongoing margin pressures raise concerns about its long-term sustainability.<BR><BR>In summary, while there are positive aspects such as significant year-on-year revenue and profit growth, the sharp quarterly declines in profitability and margins suggest underlying operational challenges. Overall, the results can be seen as good in terms of year-on-year growth but concerning when looking at the quarter-on-quarter performance.

Should I buy, sell or hold Arvee Laboratories (India) Ltd?